BriaCell Partners for Scalable Microneedle Delivery of Phase 3 Cancer Drug Bria-IMT
BCTX sits 28% above its 52-week low of $2.6 on light trading volume (0.3× avg).
Summary
BriaCell has entered a non-binding Memorandum of Understanding (MoU) with Uneedle to develop scalable microneedle technology for administering its lead Phase 3 candidate, Bria-IMT. This partnership aims to support commercial readiness and patient convenience for the drug, which is currently in a pivotal Phase 3 study. The microneedle technology is already being used in the ongoing trial. This development is a positive step towards potential commercialization, especially for a company that recently reiterated a going concern warning, though it remains contingent on regulatory approval.
At the time of this announcement, BCTX was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.60 to $31.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.